Activation of the endothelium by IL-1 alpha and glucocorticoids results in major increase of complement C3 and factor B production and generation of C3a.
Constitutive secretion of complement C3 and factor B by the endothelial cell (EC) is lowered by therapeutic concentrations of glucocorticoids such as hydrocortisone or dexamethasone, whereas regulatory protein factor H production is increased by these hormones. In contrast, the proinflammatory cytokine IL-1 alpha has a stimulatory effect on C3 and factor B secretion by the endothelium and an inhibitory effect on factor H secretion. In this study, we examined the combined effect of IL-1 alpha and glucocorticoids on C3 and factor B expression by the endothelial cell. When dexamethasone or hydrocortisone were added to IL-1 alpha, significant potentialization of IL-1 alpha-induced stimulation of C3 and factor B production was observed, occurring at various concentrations of either stimuli. Dose-response experiments indicate that, in vitro, optimal concentrations are in the range of 10(-7) to 10(-5) M for dexamethasone and 50-200 U for IL-1 alpha. In contrast, dexamethasone counteracts, in an additive way, the inhibitory effect of IL-1 alpha on regulatory complement protein factor H production by EC. Such a potentialization between glucocorticoids and IL-1 alpha was not observed for another marker of endothelial activation, IL-1 alpha-induced stimulation of coagulation tissue factor expression. The association of glucocorticoids and IL-1 alpha therefore appears to be a specific and major stimulus for the secretion of complement C3 and factor B, two acute-phase proteins, by the endothelium. As a result of the in vitro endothelium stimulation by glucocorticoids and IL-1 alpha, C3a is generated in the vicinity of the endothelial cell. This study further suggests that complement activation, with its deleterious consequences, may result from the stimulation of endothelium in situations where high levels of IL-1 alpha and endogenous glucocorticoids coexist, such as in septic shock.
Coulpier
M
M
INSERM U78, Bois-Guillaume, France.
Andreev
S
S
Lemercier
C
C
Dauchel
H
H
Lees
O
O
Fontaine
M
M
Ripoche
J
J
D002478:Cells, Cultured; D003176:Complement C3 / Q000096:biosynthesis / Q000235:genetics; D015926:Complement C3a / Q000096:biosynthesis; D011415:Complement Factor B / Q000096:biosynthesis / Q000235:genetics; D017242:Complement Factor H / Q000096:biosynthesis; D003165:Complement System Proteins / Q000096:biosynthesis*; D003907:Dexamethasone / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis / Q000096:biosynthesis; D017472:Receptors, Interleukin-1 / Q000096:biosynthesis; D014470:Umbilical Cord / Q000166:cytology
C493495:CFH protein, human; D003176:Complement C3; D005938:Glucocorticoids; D007375:Interleukin-1; D012333:RNA, Messenger; D017472:Receptors, Interleukin-1; D003907:Dexamethasone; D015926:Complement C3a; D017242:Complement Factor H; D003165:Complement System Proteins; D011415:Complement Factor B